Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
122 | 4188 | 36.6 | 75% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
390 | 16316 | MEDICATION ADHERENCE//JOURNAL OF HUMAN HYPERTENSION//BLOOD PRESSURE CONTROL |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | AMLODIPINE | Author keyword | 29 | 15% | 4% | 175 |
2 | BLOOD PRESSURE CONTROL | Author keyword | 25 | 23% | 2% | 97 |
3 | ANTIHYPERTENSIVE THERAPY | Author keyword | 25 | 18% | 3% | 128 |
4 | ANTIHYPERTENSIVE TREATMENT | Author keyword | 23 | 19% | 3% | 108 |
5 | HYDROCHLOROTHIAZIDE | Author keyword | 23 | 15% | 3% | 139 |
6 | TARGET BLOOD PRESSURE | Author keyword | 21 | 61% | 1% | 23 |
7 | BLOOD PRESSURE LOWERING | Author keyword | 21 | 55% | 1% | 26 |
8 | INDAPAMIDE | Author keyword | 21 | 29% | 1% | 61 |
9 | SINGLE PILL COMBINATION | Author keyword | 20 | 67% | 0% | 18 |
10 | J CURVE | Author keyword | 19 | 41% | 1% | 37 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | AMLODIPINE | 29 | 15% | 4% | 175 | Search AMLODIPINE | Search AMLODIPINE |
2 | BLOOD PRESSURE CONTROL | 25 | 23% | 2% | 97 | Search BLOOD+PRESSURE+CONTROL | Search BLOOD+PRESSURE+CONTROL |
3 | ANTIHYPERTENSIVE THERAPY | 25 | 18% | 3% | 128 | Search ANTIHYPERTENSIVE+THERAPY | Search ANTIHYPERTENSIVE+THERAPY |
4 | ANTIHYPERTENSIVE TREATMENT | 23 | 19% | 3% | 108 | Search ANTIHYPERTENSIVE+TREATMENT | Search ANTIHYPERTENSIVE+TREATMENT |
5 | HYDROCHLOROTHIAZIDE | 23 | 15% | 3% | 139 | Search HYDROCHLOROTHIAZIDE | Search HYDROCHLOROTHIAZIDE |
6 | TARGET BLOOD PRESSURE | 21 | 61% | 1% | 23 | Search TARGET+BLOOD+PRESSURE | Search TARGET+BLOOD+PRESSURE |
7 | BLOOD PRESSURE LOWERING | 21 | 55% | 1% | 26 | Search BLOOD+PRESSURE+LOWERING | Search BLOOD+PRESSURE+LOWERING |
8 | INDAPAMIDE | 21 | 29% | 1% | 61 | Search INDAPAMIDE | Search INDAPAMIDE |
9 | SINGLE PILL COMBINATION | 20 | 67% | 0% | 18 | Search SINGLE+PILL+COMBINATION | Search SINGLE+PILL+COMBINATION |
10 | J CURVE | 19 | 41% | 1% | 37 | Search J+CURVE | Search J+CURVE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ISOLATED SYSTOLIC HYPERTENSION | 254 | 34% | 15% | 609 |
2 | SWEDISH TRIAL | 142 | 77% | 2% | 98 |
3 | ANTIHYPERTENSIVE DRUG TREATMENT | 114 | 65% | 3% | 108 |
4 | LIPID LOWERING TREATMENT | 104 | 37% | 5% | 227 |
5 | ACTIVE TREATMENT | 100 | 57% | 3% | 120 |
6 | CALCIUM CHANNEL BLOCKER | 83 | 28% | 6% | 248 |
7 | FIXED DOSE COMBINATIONS | 76 | 66% | 2% | 70 |
8 | MAJOR CARDIOVASCULAR EVENTS | 74 | 53% | 2% | 99 |
9 | PROSPECTIVELY DESIGNED OVERVIEWS | 65 | 52% | 2% | 87 |
10 | CARDIOVASCULAR MORBIDITY | 58 | 26% | 5% | 195 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL HYPERTENSION | 13 | 12% | 3% | 105 |
2 | BLOOD PRESSURE | 12 | 11% | 2% | 102 |
3 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 4 | 10% | 1% | 36 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) | 2014 | 712 | 28 | 75% |
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 2009 | 614 | 252 | 38% |
2013 ESH/ESC Guidelines for the management of arterial hypertension | 2013 | 518 | 655 | 17% |
2007 guidelines for the management of arterial hypertension | 2007 | 2620 | 687 | 18% |
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | 2003 | 5625 | 283 | 21% |
Chlorthalidone Compared With Hydrochlorothiazide in Reducing Cardiovascular Events Systematic Review and Network Meta-Analyses | 2012 | 43 | 38 | 66% |
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | 1997 | 3942 | 183 | 20% |
Effects of Blood Pressure Reduction in Mild Hypertension A Systematic Review and Meta-analysis | 2015 | 5 | 29 | 41% |
When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal | 2009 | 86 | 50 | 76% |
The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials | 2011 | 51 | 33 | 73% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CARL EDYTH LINDNER EDUC | 9 | 55% | 0.3% | 11 |
2 | BLOOD P SURE LOWERING TREATMENT TRIALISTS A | 8 | 100% | 0.1% | 5 |
3 | FISIOL CLIN IPERTENS | 8 | 18% | 1.0% | 41 |
4 | PROG S ABORAT GRP | 7 | 64% | 0.2% | 7 |
5 | HYPERTENS CARDIOVASC REHABIL UNIT | 7 | 17% | 0.9% | 38 |
6 | HYPERTENS DIS SECT | 5 | 42% | 0.2% | 10 |
7 | PRIMARY CARE SERV LINE | 5 | 47% | 0.2% | 8 |
8 | UNIDAD HIPERTENS | 4 | 17% | 0.6% | 24 |
9 | HIGH BLOOD P SURE EDUC PROGRAM | 4 | 47% | 0.2% | 7 |
10 | DOUALA CARDIOVASC | 4 | 75% | 0.1% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000209318 | PULSE PRESSURE//PSEUDOHYPERTENSION//PENAZ METHOD |
2 | 0.0000188704 | PREHYPERTENSION//HYPERTENSION PREVALENCE//HIGH NORMAL BLOOD PRESSURE |
3 | 0.0000152965 | MRC TRIAL//ABORAT PREVENT TREATMENT CARDIOVASC DIS//CLIN EPIDEMIOL HLTH CARE PROGRAM MED |
4 | 0.0000150344 | TRANDOLAPRIL//MULTI PHOTON CONTAMINATION//VERAPAMIL SR TRANDOLAPRIL COMBINATION THERAPY |
5 | 0.0000140664 | LERCANIDIPINE//LACIDIPINE//LERCANIDIPINE HYDROCHLORIDE |
6 | 0.0000106018 | INTEGRATED CARDIOVASC CLIN NETWORK SA//PREVENTAT HLTH//ANGIOTENSIN CONVERTING ENZYME INHIBITOR THERAPY |
7 | 0.0000096673 | CANDESARTAN CILEXETIL//ANGIOTENSIN II RECEPTOR ANTAGONIST//LOSARTAN |
8 | 0.0000091755 | DUAL BLOCKADE//RENOPROTECTION//NONDIABETIC RENAL DISEASE |
9 | 0.0000088174 | INDAPAMIDE//CLIN NUTR METAB DIS//PHARMACOL PHYSIOPATHOL CARDIOVASC |
10 | 0.0000087901 | AMLODIPINE//DILTIAZEM CR//BESYLATE |